JP2021512881A5 - - Google Patents

Info

Publication number
JP2021512881A5
JP2021512881A5 JP2020542273A JP2020542273A JP2021512881A5 JP 2021512881 A5 JP2021512881 A5 JP 2021512881A5 JP 2020542273 A JP2020542273 A JP 2020542273A JP 2020542273 A JP2020542273 A JP 2020542273A JP 2021512881 A5 JP2021512881 A5 JP 2021512881A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
concentration
present
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021512881A (ja
JP7407118B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/017294 external-priority patent/WO2019157340A1/en
Publication of JP2021512881A publication Critical patent/JP2021512881A/ja
Publication of JP2021512881A5 publication Critical patent/JP2021512881A5/ja
Priority to JP2023145922A priority Critical patent/JP7627730B2/ja
Application granted granted Critical
Publication of JP7407118B2 publication Critical patent/JP7407118B2/ja
Priority to JP2025011263A priority patent/JP2025063316A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542273A 2018-02-08 2019-02-08 低ｐＨ医薬抗体製剤 Active JP7407118B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023145922A JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862628267P 2018-02-08 2018-02-08
US62/628,267 2018-02-08
US201962799577P 2019-01-31 2019-01-31
US62/799,577 2019-01-31
PCT/US2019/017294 WO2019157340A1 (en) 2018-02-08 2019-02-08 Low ph pharmaceutical antibody formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145922A Division JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤

Publications (3)

Publication Number Publication Date
JP2021512881A JP2021512881A (ja) 2021-05-20
JP2021512881A5 true JP2021512881A5 (https=) 2022-02-16
JP7407118B2 JP7407118B2 (ja) 2023-12-28

Family

ID=65576686

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020542273A Active JP7407118B2 (ja) 2018-02-08 2019-02-08 低ｐＨ医薬抗体製剤
JP2023145922A Active JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A Pending JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023145922A Active JP7627730B2 (ja) 2018-02-08 2023-09-08 低ｐＨ医薬抗体製剤
JP2025011263A Pending JP2025063316A (ja) 2018-02-08 2025-01-27 低ｐＨ医薬抗体製剤

Country Status (10)

Country Link
US (2) US20210047407A1 (https=)
EP (1) EP3749363A1 (https=)
JP (3) JP7407118B2 (https=)
AU (2) AU2019216759A1 (https=)
CA (1) CA3089906A1 (https=)
MA (1) MA51747A (https=)
MX (2) MX2020008219A (https=)
TW (2) TWI860988B (https=)
UY (1) UY38080A (https=)
WO (1) WO2019157340A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3653221T5 (da) 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
IL317989A (en) 2016-08-17 2025-02-01 Compugen Ltd Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
IL317134A (en) 2016-12-21 2025-01-01 Teneobio Inc An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
WO2019204646A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
TW202519260A (zh) * 2018-07-02 2025-05-16 美商安進公司 抗steap1抗原結合蛋白
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
AU2019359475A1 (en) 2018-10-12 2021-05-20 Xencor, Inc. PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
CN113438961A (zh) 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
CN120241997A (zh) 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP2023500651A (ja) * 2019-11-04 2023-01-10 コンピュジェン リミテッド 抗ｐｖｒｉｇ抗体製剤および抗ｐｄ－１抗体による併用療法
US11976133B2 (en) * 2020-01-31 2024-05-07 Gensun Biopharma Inc. Bispecific T cell engagers
EP4200333A1 (en) * 2020-08-24 2023-06-28 Amgen Inc. Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine
KR20250112314A (ko) * 2022-01-10 2025-07-23 페노믹 에이아이 항-콜라겐 삼중 나선 반복 함유 1(cthrc1) 항체 및 이를 사용하는 방법
TW202515613A (zh) 2023-08-21 2025-04-16 德商安美基研究（慕尼黑）公司 用於治療前列腺癌之方法
TW202513554A (zh) 2023-08-21 2025-04-01 德商安美基研究（慕尼黑）公司 用於治療前列腺癌之組合療法
WO2025128807A1 (en) * 2023-12-13 2025-06-19 Amgen Inc. Radiolabeled compounds for the detection of steap1
WO2026039321A1 (en) 2024-08-12 2026-02-19 Amgen, Inc. Methods for treating prostate cancer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1998048032A2 (en) 1997-04-21 1998-10-29 Donlar Corporation POLY-(α-L-ASPARTIC ACID), POLY-(α-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE
US7449443B2 (en) 2000-03-23 2008-11-11 California Institute Of Technology Method for stabilization of proteins using non-natural amino acids
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
WO2003073238A2 (en) 2002-02-27 2003-09-04 California Institute Of Technology Computational method for designing enzymes for incorporation of amino acid analogs into proteins
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
WO2004039337A2 (en) 2002-10-31 2004-05-13 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
WO2005035727A2 (en) 2003-10-09 2005-04-21 Ambrx, Inc. Polymer derivatives
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20160355591A1 (en) * 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
TW200826974A (en) * 2006-09-07 2008-07-01 Kirin Pharma Kk Stable lyophilized pharmaceutical preparation comprising antibody
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
US9527926B2 (en) * 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US8820052B2 (en) 2012-02-09 2014-09-02 Ford Global Technologies, Llc Liquid reductant system and method for operation of the liquid reductant system
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR102211837B1 (ko) 2013-01-14 2021-02-03 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10858417B2 (en) * 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
CN104474547A (zh) * 2015-01-07 2015-04-01 蓝佳堂生物医药（福建）有限公司 一种抗阴道感染免疫球蛋白复合抑菌剂
TWI796283B (zh) * 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
ITUB20152921A1 (it) 2015-08-06 2017-02-06 Lino Manfrotto Co S P A Supporto orientabile per apparecchiature video-fotografiche
JOP20170017B1 (ar) * 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
JP7010854B2 (ja) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド 二重特異性チェックポイント阻害剤抗体

Similar Documents

Publication Publication Date Title
JP2021512881A5 (https=)
JP7080263B2 (ja) 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤
TWI860988B (zh) 低ph藥物製劑
TWI911431B (zh) 抗rsv單株抗體配製物
CN106999591B (zh) 一种抗pd-1抗体制剂及其在医药上的应用
JP2021504372A5 (https=)
US12251474B2 (en) Process for lyophilized pharmaceutical formulations of a therapeutic protein
KR20090021298A (ko) 항-ｅｇｆｒ 항체의 동결건조 제제
WO2020094122A1 (zh) 一种TGF-β受体融合蛋白药物组合物及其用途
JP2022036932A5 (https=)
FI3576788T3 (fi) Matalan ph-arvon omaava farmaseuttinen koostumus, joka käsittää t-soluihin sitoutuvia vasta-ainekonstrukteja
CN102770157A (zh) 抗体的配制品
JP2016533335A5 (https=)
JP2016534052A5 (https=)
CN115916816B (zh) 抗血清白蛋白抗体
KR102399028B1 (ko) 이중-특이적 항원-결합 폴리펩티드
US20220378908A1 (en) Compositions and methods for minimizing protein loss at low protein concentrations
JP2023515196A (ja) 脂肪酸分子とコンジュゲートされた抗体及びその使用
EP4190352B1 (en) Formulation of novel bispecific anti-cd3/cd20 polypeptide complex
KR20230058432A (ko) 약제학적 제형
US20250108122A1 (en) Pharmaceutical composition comprising anti-cd79b antibody-drug conjugate and use thereof
US20260062469A1 (en) Compositions and methods for linear and conformational site-specific antibodies and methods of making the same
KR20200012937A (ko) c-Met 항체 약물 접합체를 포함하는 약학 조성물 및 그의 용도
JP2024538140A5 (https=)
US20230167176A1 (en) Pharmaceutical formulation